Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
SUMMIT (PUMA-NER-5201) Basket Trial
EDGAR Filing Documents for 0001437749-22-000622
208051Orig1s000
Kam Zaki on Twitter: "an interim analysis of Phase II study (n=14) showed the combination of pyrotinib and apatinib has an ORR of 35.7% when used as second line treatment in patients
SUMMIT (PUMA-NER-5201) Basket Trial
Neratinib Shows Early Activity in EGFR Exon 18–Mutated, Metastatic NSCLC
Full article: Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC
5100 Piedra Alta Ln NE, Albuquerque, NM 87111 | realtor.com®
208051Orig1s000
KRAS, HER2 & ALK: targeted options and sequencing issues - memoinOncology
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies - Journal of Thoracic Oncology
KRAS, HER2 & ALK: targeted options and sequencing issues - memoinOncology
SUMMIT (PUMA-NER-5201) Basket Trial
Targeting HER2 genomic alterations in non-small cell lung cancer - ScienceDirect
PUMA Background
2018 Scientific Report
Neratinib-based combination therapy in HER2-Mutant lung cancer | VJOncology
Effective Management and Prevention of Neratinib-Induced Diarrhea
Reunion Puma and Da Vinci - gut-aiderbichl.com
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
